DOCSLIB.ORG

Swedish Code of Statutes

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Swedish Code of Statutes 1. ------IND- 2018 0506 S-- EN- ------ 20190508 --- --- FINAL Swedish Code of Statutes Ordinance amending the Ordinance (1999:58) banning certain products SFS 2018:1587 that are harmful to health Published Issued on 4 October 2018 on 9 October 2018 The Government hereby lays down1 that the annex to the Ordinance (1999:58) prohibiting certain products that are harmful to health shall read as set out below. ___________ This ordinance shall enter into force on 12 November 2018. On behalf of the government ANNIKA STRANDHÄLL Kjell Rempler (Ministry of Health and Social Affairs) 1 See Directive (EU) 2015/1535 of the European Parliament and of the Council of 9 September 2015 laying down a procedure for the provision of information in the field of technical regulations and of rules on Information Society services. 2 Annex SFS 2018:1587 List of products to be regarded as products that are harmful to health in accordance with the Ordinance prohibiting certain products that are harmful to health N-methyl-1-(3,4-methylenedioxyphenyl)-2-butylamine (MBDB) 1-(3,4-methylenedioxyphenyl)-2-butylamine (BDB) 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) 5-methoxy-N,N-diisopropyltryptamine (5-MeO-DiPT) 5-methoxy-alphamethyltryptamine (5-MeO-AMT) 2,5-dimethoxy-4-ethylphenethylamine (2C-E) alpha-methyltryptamine (AMT) 2,5-dimethoxy-4-chlorophenethylamine (2C-C) 2,5-dimethoxy-4-methylphenethylamine (2C-D) 4-acetoxy-N,N-diisopropyltryptamine (4-AcO-DiPT) 4-hydroxy-N,N-diisopropyltryptamine (4-HO-DiPT) gamma-butyrolactone (GBL) 1,4-butanediol (1,4-BD) 4-acetoxy-N,N-methylisopropyltryptamine (4-AcO-MiPT) 4-hydroxy-N,N-methylisopropyltryptamine (4-HO-MiPT) 4-acetoxy-N,N-diethyltryptamine (4-AcO-DET) 4-hydroxy-N,N-diethyltryptamine (4-HO-DET) 1-(3-trifluoromethylphenyl)piperazine (TFMPP) 2,5-dimethoxy-4-isopropylthiophenethylamine (2C-T-4) [2,3-dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo[1,2,3- de]-1,4-benzoxazin-6-yl]-1-naphtalenylmethanone (WIN 55,212-2) 5-(1,1-dimethylheptyl)-2-[5-hydroxy-2-(3-hydroxypropyl)cyclohexyl]phenol (CP 55,940) (2-methyl-1-pentylindol-3-yl)-(naphthalen-1-yl)methanone (JWH-007) (2-methyl-1-propyl-1H-indol-3-yl)-1-naphthalenylmethanone (JWH-015) (1-hexyl-1H-indol-3-yl)-1-naphthalenylmethanone (JWH-019) 2-methylnaphthalen-1-yl-(butylindol-3-yl)methanone (JWH-073 methyl derivative) 4-methoxynaphthalen-1-yl-(1-pentylindol-2-methyl-3-yl)methanone (JWH- 098) 1-hexyl-2-phenyl-4-(1-naphthoyl)pyrrole (JWH-147) (4-methoxyphenyl)(1-pentyl-1H-indol-3-yl)methanone (RCS-4) 4-methylhexan-2-amine (DMAA) 4-(2-aminopropyl)benzofuran (4-APB) 5-(2-aminopropyl)benzofuran (5-APB) 6-(2-aminopropyl)benzofuran (6-APB) 1-(1-benzofuran-5-yl)-N-methylpropan-2-amine (5-MAPB) 1-(5-fluoropentyl)-N-tricyclo[3.3.1.13,7]dec-1-yl-1H-indole-3-carboxamide (STS-135) 2 Latest wording 2018:539. The amendment concerns, among other things, the removal of ‘(1-pentyl-1H- indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone (UR-144)’; ‘1-(5-fluoropentyl)-1H-indole-3- carboxylic acid 8-quinolinyl ester (5F-PB22)’; ‘N-[1-(aminocarbonyl)-2-methylpropyl]-1- (cyclohexylmethyl)-1H-indazole-3-carboxamide (AB-CHMINACA)’; ‘N-(1-amino-3-methyl-1-oxobutan-2- yl)-1-pentyl-1H-indazole-3-carboxamide (AB-PINACA)’; ‘methyl-2-(1-(5-fluoropentyl)-1H-indazole-3- carboxamido)-3,3-dimethylbutanoate (5F-MDMB-PINACA)’; and ‘N-[1-(2-phenylethyl)piperidin-4-yl]-N- (2-fluorophenyl)propanamide (2-fluorofentanyl)’ from the list. 2 3,7 1-pentyl-N-tricyclo[3.3.1.1 ]dec-1-yl-1H-indole-3-carboxamide (APICA SFS 2018:1587 [JWH-018 adamantyl carboxamide]) 1-pentyl-N-tricyclo[3.3.1.13,7]dec-1-yl-1H-indazole-3-carboxamide (AKB48) (1-pentyl-1H-indole-3-yl)-tricyclo[3.3.1.13,7]dec-1-yl-methanone (AB-001) 1-[(5-chloropentyl)-1H-indol-3-yl]-(naphthalen-1-yl)methanone (JWH-018 N-[5-chloropentyl] derivative) N-[1-(aminocarbonyl)-2-methylpropyl]-1-[(4-fluorophenyl)methyl]-1H- indazole-3-carboxamide (AB FUBINACA) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-((4-fluorophenyl)methyl)-1H- indazole-3-carboxamide (ADB-FUBINACA) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1H-indazole-3- carboxamide (5F-AB-PINACA) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indole-3- carboxamide (ADBICA) quinolin-8-yl-1-pentyl-1H-indole-3-carboxylate (PB-22) quinolin-8-yl-1-(4-flourobenzyl)-1H-indole-3-carboxylate (FUB-PB-22) naphthalen-1-yl-1-(4-fluorobenzyl)-1H-indole-3-carboxylate (FDU-PB-22) quinolin-8-yl-1-(5-fluoropentyl)-1H-indazole-3-carboxylate (5F-PB-22 indazole) quinolin-8-yl-1-(cyclohexylmethyl)-1H-indole-3-carboxylate (BB-22) 4-hydroxy-3,3,4-trimethyl-1-(1-pentyl-1H-indol-3-yl)pentan-1-one (4- HTMPIPO) (1-heptyl-1H-indol-3-yl) (2,2,3,3-tetramethylcyclopropyl)methanone (UR- 144 heptyl derivative) N-benzyl-1-(5-fluoropentyl)-1H-indole-3-carboxamide (5F-SDB-006) N-benzyl-1-pentyl-1H-indole-3-carboxamide (SDB-006) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3- carboxamide (ADB-PINACA) N-(naphthalen-1-yl)-1-pentyl-1H-indazole-3-carboxamide (MN-18) 1-(5-fluoropentyl)-N-(naphthalen-1-yl)-1H-indole-3-carboxamide (5F-NNEI) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1H-indole-3- carboxamide (5F-AB-144) (1-(5-fluoropentyl)-1H-indazol-3-yl)(naphthalen-1-yl)methanone (THJ-2201) [1-(5-fluoropentyl)-1H-benzo[d]imidazol-2-yl](naphthalen-1-yl)methanone (FUBIMINA) methyl-2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3- methylbutanoate (5F-AMB) 1-(5-fluoropentyl)-N-(naphthalen-1-yl)-1H-indazole-3-carboxamide (5F-MN-18) 1-(5-fluoropentyl)-N-(naphthalen-1-yl)-1H-pyrrolo[3,2-c]pyridine-3- carboxamide (5F-PCN) naphthalen-1-yl-1-(5-fluoropentyl)-1H-indazole-3-carboxylate (5F-SDB-005) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-[(2-fluorophenyl)methyl]-1H- indazole-3-carboxamide (AB-FUBINACA 2-fluorobenzyl isomer) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H- indazole-3-carboxamide (ADB-CHMINACA) 7-chloro-N-[1-[((2-((cyclopropylsulfonyl)amino)-ethyl)amino)carbonyl]-2,2- dimethyl-propyl]-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide (ADSB-FUB- 187) 3 adamant-1-yl-(1-[(N-methylpiperidin-2-yl)methyl]-1H-indol-3-yl)methanone SFS 2018:1587 (AM-1248) N-(2-phenylpropan-2-yl)-1-(5-fluoropentyl)-1H-indole-3-carboxamide (CUMYL-5F-PICA) 1-(5-fluoropentyl)-N-(2-phenylpropan-2-yl)-1H-indole-3-carboxamide (CUMYL-5F-PINACA, SGT-25) 1-butyl-N-(2-phenylpropan-2-yl)-1H-indole-3-carboxamide (CUMYL-BICA) N-(2-phenylpropan-2-yl)-1-pentyl-1H-indole-3-carboxamide (CUMYL- PICA) N-(2-phenylpropan-2-yl)-1-pentyl-1H-indazole-3-carboxamide (CUMYL- PINACA) N-(2-phenylpropan-2-yl)-1-((tetrahydro-2H-pyran-4-yl)methyl)-1H-indazole- 3-carboxamide (CUMYL-THPINACA) (1-(5-fluoropentyl)-1H-indazol-3-yl)(2,2,3,3- tetramethylcyclopropyl)methanone (FAB-144) N-(adamant-1-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide (FUB- AKB48) methyl-2-(1-(4-fluorobenzyl)-1H-indazole-3-carboxamido)-3- methylbutanoate (FUB-AMB) methyl-2-([1-(5-fluoropentyl)-1H-indol-3-yl]carboxamide)-3- methylbutanoate (I-AMB) (4-methylpiperazin-1-yl)(1-pentyl-1H-indol-3-yl)methanone (mepirapim) naphthalen-1-yl-1-(5-fluoropentyl)-1H-indole-3-carboxylate (NM-2201) N-(1-amino-3-phenyl-1-oxopropan-2-yl)-1-(5-fluoropentyl)-1H-indole-3- carboxamide (PX-1) N-(1-amino-3-phenyl-1-oxopropan-2-yl)-1-(5-fluoropentyl)-1H-indazole-3- carboxamide (PX-2) naphthalen-1-yl-(1-pentyl-1H-indazol-3-yl)methanone (THJ-018) 1-(3,4-methylenedioxyphenyl)-2-(pyrrolidin-1-yl)butan-1-one (MDPBP) 2-(pyrrolidin-1-yl)-1-(thiophen-2-yl)butan-1-one (alpha-PBT) 2-(pyrrolidin-1-yl)-1-(thiophen-2-yl)pentan-1-one (alpha-PVT) 1-(4-methylphenyl)-2-(pyrrolidin-1-yl)hexan-1-one (MPHP) 1-(4-chlorophenyl)-2-(pyrrolidin-1-yl)propan-1-one (4Cl-alpha-PPP) 1-phenyl-2-(pyrrolidin-1-yl)hexan-1-one (alpha-PHP) 1-phenyl-2-(pyrrolidin-1-yl)heptan-1-one (alpha-PEP) 1-(2,3-dihydro-1-benzofuran-5-yl)propan-2-amine (5-APDB) 1-(2,3-dihydro-1-benzofuran-6-yl)propan-2-amine (6-APDB) 1-(1-benzofuran-6-yl)-N-methylpropan-2-amine (6-MAPB) 2-(ethylamino)-1-(4-methylphenyl)pentan-1-one (N-ethyl-4'- methylnorpentedrone) [1-[(tetrahydro-2H-pyran-4-yl)methyl]-1H-indol-3-yl] (2,2,3,3- tetramethylcyclopropyl)methanone (A-834735) N-(adamantan-2-yl)-1-[(tetrahydro-2H-pyran-4-yl)methyl]-1H-indazole-3- carboxamide (adamantyl-THPINACA) N-(1-amino-3.3-dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indole- 3-carboxamide (ADB-CHMICA) N-(1-amino-3-phenyl-1-oxopropan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3- carboxamide (APP-FUBINACA) naphthalen-1-yl-(9-pentyl-9H-carbazole-3-yl)methanone (EG-018) 4 (1-(4-fluorobenzyl)-1H-indol-3-yl)(2,2,3,3- SFS 2018:1587 tetramethylcyclopropyl)methanone (FUB-144) quinolin-8-yl-1-pentyl-1H-indazole-3-carboxylate (PB-22 indazole) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(2-fluoropentyl)-1H-indazole-3- carboxamide (AB-PINACA N-(2-fluoropentyl) isomer, 2F-AB-PINACA) N-(1-amino-3-phenyl-1-oxopropan-2-yl)-1-(cyclohexylmethyl)-1H-indazole- 3-carboxamide (APP-CHMINACA) N-(adamantyl)-1-(5-chloropentyl)-1H-indazole-3-carboxamide (5C-AKB48) methyl-2-(1-(4-fluorobenzyl)-1H-indole-3-carboxamide)-3.3- dimethylbutanoate (MDMB-FUBICA) methyl-2-(1-(4-fluorobenzyl)-1H-indazole-3-carboxamide)-3.3- dimethylbutanoate (MDMB-FUBINACA) naphthalen-1-yl-1-pentyl-1H-indazole-3-carboxylate (SDB-005) N-(1-amino-3.3-dimethyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1H-indazole- 3-carboxamide (5F-ADB-PINACA) N-ethyl-1,2-diphenylethanamine (ephenidine, NEDPA) N-(1,2-diphenylethyl)propan-2-amine (NPDPA) N-[1-(2-phenylethyl)piperidin-4-yl]-N-(4-fluorophenyl)butanamide (4-fluoro- butyrfentanyl, 4F-BF) 1-(4-chlorophenyl)-2-(methylamino)propan-1-one (4-CMC, clephedrone) 1-(3-chlorophenyl)-2-(methylamino)propan-1-one (3-CMC, clophedrone)
Load more

Recommended publications
  • FSI-D-16-00226R1 Title
    Elsevier Editorial System(tm) for Forensic Science International Manuscript Draft Manuscript Number: FSI-D-16-00226R1 Title: An overview of Emerging and New Psychoactive Substances in the United Kingdom Article Type: Review Article Keywords: New Psychoactive Substances Psychostimulants Lefetamine Hallucinogens LSD Derivatives Benzodiazepines Corresponding Author: Prof. Simon Gibbons, Corresponding Author's Institution: UCL School of Pharmacy First Author: Simon Gibbons Order of Authors: Simon Gibbons; Shruti Beharry Abstract: The purpose of this review is to identify emerging or new psychoactive substances (NPS) by undertaking an online survey of the UK NPS market and to gather any data from online drug fora and published literature. Drugs from four main classes of NPS were identified: psychostimulants, dissociative anaesthetics, hallucinogens (phenylalkylamine-based and lysergamide-based materials) and finally benzodiazepines. For inclusion in the review the 'user reviews' on drugs fora were selected based on whether or not the particular NPS of interest was used alone or in combination. NPS that were use alone were considered. Each of the classes contained drugs that are modelled on existing illegal materials and are now covered by the UK New Psychoactive Substances Bill in 2016. Suggested Reviewers: Title Page (with authors and addresses) An overview of Emerging and New Psychoactive Substances in the United Kingdom Shruti Beharry and Simon Gibbons1 Research Department of Pharmaceutical and Biological Chemistry UCL School of Pharmacy
    [Show full text]
  • Recommended Methods for the Identification and Analysis of Fentanyl and Its Analogues in Biological Specimens
    Recommended methods for the Identification and Analysis of Fentanyl and its Analogues in Biological Specimens MANUAL FOR USE BY NATIONAL DRUG ANALYSIS LABORATORIES Laboratory and Scientific Section UNITED NATIONS OFFICE ON DRUGS AND CRIME Vienna Recommended Methods for the Identification and Analysis of Fentanyl and its Analogues in Biological Specimens MANUAL FOR USE BY NATIONAL DRUG ANALYSIS LABORATORIES UNITED NATIONS Vienna, 2017 Note Operating and experimental conditions are reproduced from the original reference materials, including unpublished methods, validated and used in selected national laboratories as per the list of references. A number of alternative conditions and substitution of named commercial products may provide comparable results in many cases. However, any modification has to be validated before it is integrated into laboratory routines. ST/NAR/53 Original language: English © United Nations, November 2017. All rights reserved. The designations employed and the presentation of material in this publication do not imply the expression of any opinion whatsoever on the part of the Secretariat of the United Nations concerning the legal status of any country, territory, city or area, or of its authorities, or concerning the delimitation of its frontiers or boundaries. Mention of names of firms and commercial products does not imply the endorse- ment of the United Nations. This publication has not been formally edited. Publishing production: English, Publishing and Library Section, United Nations Office at Vienna. Acknowledgements The Laboratory and Scientific Section of the UNODC (LSS, headed by Dr. Justice Tettey) wishes to express its appreciation and thanks to Dr. Barry Logan, Center for Forensic Science Research and Education, at the Fredric Rieders Family Founda- tion and NMS Labs, United States; Amanda L.A.
    [Show full text]
  • UNODC, Synthetic Drugs in East and Southeast Asia
    Synthetic Drugs in East and Southeast Asia Latest developments and challenges May 2020 Global SMART Programme Copyright © 2020, United Nations Office on Drugs and Crime (UNODC). This publication may be reproduced in whole or in part and in any form for educational or non-profit purposes without special permission from the copyright holder, provided acknowledgement of the source is made. UNODC would appreciate receiving a copy of any publication that uses this publication as a source. Acknowledgements This report was prepared by the Global Synthetic Monitoring: Analyses, Reporting and Trends (SMART) Programme, Laboratory and Scientific Section with the support of the UNODC Regional Office for Southeast Asia and the Pacific. Supervision, direction and review Justice Tettey, Chief, Laboratory and Scientific Section Jeremy Douglas, Regional Representative, Southeast Asia and the Pacific Research and drafting Martin Raithelhuber, Illicit Synthetic Drugs Expert Tun Nay Soe, Inter-regional Programme Coordinator Inshik Sim, Drug Programme Analyst, Southeast Asia and the Pacific Joey Yang Yi Tan, Junior Professional Officer in Drug Research Graphic design and layout Akara Umapornsakula, Graphic Designer Administrative support Jatupat Buasipreeda, Programme Assistant The present report also benefited from the expertise and valuable contributions of UNODC colleagues in the Laboratory and Scientific Section and the Regional Office for Southeast Asia and the Pacific, including Tsegahiwot Abebe Belachew, Rebecca Miller, Reiner Pungs, and John Wojcik. Disclaimer This report has not been formally edited. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of UNODC or the Secretariat of the United Nations concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries.
    [Show full text]
  • WHO Expert Committee on Drug Dependence
    WHO Technical Report Series 1034 This report presents the recommendations of the forty-third Expert Committee on Drug Dependence (ECDD). The ECDD is responsible for the assessment of psychoactive substances for possible scheduling under the International Drug Control Conventions. The ECDD reviews the therapeutic usefulness, the liability for abuse and dependence, and the public health and social harm of each substance. The ECDD advises the Director-General of WHO to reschedule or to amend the scheduling status of a substance. The Director-General will, as appropriate, communicate the recommendations to the Secretary-General of the United Nations, who will in turn communicate the advice to the Commission on Narcotic Drugs. This report summarizes the findings of the forty-third meeting at which the Committee reviewed 11 psychoactive substances: – 5-Methoxy-N,N-diallyltryptamine (5-MeO-DALT) WHO Expert Committee – 3-Fluorophenmetrazine (3-FPM) – 3-Methoxyphencyclidine (3-MeO-PCP) on Drug Dependence – Diphenidine – 2-Methoxydiphenidine (2-MeO-DIPHENIDINE) Forty-third report – Isotonitazene – MDMB-4en-PINACA – CUMYL-PEGACLONE – Flubromazolam – Clonazolam – Diclazepam The report also contains the critical review documents that informed recommendations made by the ECDD regarding international control of those substances. The World Health Organization was established in 1948 as a specialized agency of the United Nations serving as the directing and coordinating authority for international health matters and public health. One of WHO’s constitutional functions is to provide objective, reliable information and advice in the field of human health, a responsibility that it fulfils in part through its extensive programme of publications. The Organization seeks through its publications to support national health strategies and address the most pressing public health concerns of populations around the world.
    [Show full text]
  • Test Purchase, Synthesis and Characterization of 2- Methoxydiphenidine (MXP) and Differentiation from Its Meta- and Para-Substituted Isomers
    Drug Testing and Analysis (accepted, uncorrected) Test purchase, synthesis and characterization of 2- methoxydiphenidine (MXP) and differentiation from its meta- and para-substituted isomers Gavin McLaughlin, a,b Noreen Morris, a Pierce V. Kavanagh, b John D. Power, b John O’Brien, c Brian Talbot, d Simon P. Elliott, e Jason Wallach, f Khoa Hoang, g Hamilton Morris, h Simon D. Brandt i* a Department of Life and Physical Sciences, School of Science, Athlone Institute of Technology, Dublin Road, Westmeath, Ireland b Department of Pharmacology and Therapeutics, School of Medicine, Trinity Centre for Health Sciences, St. James Hospital, Dublin 8, Ireland c School of Chemistry, Trinity College, Dublin 2, Ireland d School of Pharmacy and Pharmaceutical Sciences, Trinity College, Dublin 2, Ireland e ROAR Forensics, Malvern Hills Science Park, Geraldine Road, WR14 3SZ, UK f Department of Pharmaceutical Sciences, Philadelphia College of Pharmacy, University of the Sciences, Philadelphia, PA 19104, USA g Department of Chemistry and Biochemistry, University of the Sciences, Philadelphia, PA 19104, USA hThe New School for Social Research, Department of Anthropology, 66 West 12th Street, NY 10011, New York, USA i School of Pharmacy and Biomolecular Sciences, Liverpool John Moores University, Byrom Street, Liverpool L3 3AF, UK *Correspondence to: Simon D. Brandt, School of Pharmacy and Biomolecular Sciences, Liverpool John Moores University, Byrom Street, Liverpool, L3 3AF, UK. E- Mail: [email protected] Running title: Characterization of 2-, 3- and 4-methoxydiphenidine isomers 1 Abstract The structurally diverse nature of the 1,2-diphenylethylamine template provides access to a range of substances for drug discovery work but some have attracted attention as ‘research chemicals’.
    [Show full text]
  • 1,2-Diphenylethylamine Designer Drugs
    1,2-Diphenylethylamine Designer Drugs Metabolism Studies and Toxicological Analysis Using Gas Chromatography-Mass Spectrometry and Liquid Chromatography-Mass Spectrometry Coupled to Low and High Resolution-Mass Spectrometry Dissertation zur Erlangung des Grades des Doktors der Naturwissenschaften der Naturwissenschaftlich-Technischen Fakultät III - Chemie, Pharmazie, Bio- und Werkstoffwissenschaften der Universität des Saarlandes von Carina Sandra Denise Wink Saarbrücken 2016 Tag des Kolloquiums: 17.06.2016 Dekan: Univ.-Prof. Dr.-Ing. Dirk Bähre Berichterstatter: Univ.-Prof. Dr. rer. nat. Dr. h.c. Hans H. Maurer Univ.-Prof. Dr. rer. nat. Rolf W. Hartmann Vorsitz: Univ.-Prof. Dr. med. Veit Flockerzi Akad. Mitarbeiter: Dr. rer. nat. Josef Zapp Die nachfolgende Arbeit entstand unter der Anleitung von Herrn Professor Dr. Dr. h.c. Hans H. Maurer in der Abteilung Experimentelle und Klinische Toxikologie der Fachrichtung 2.4 Experimentelle und Klinische Pharmakologie und Toxikologie der Universität des Saarlandes in Homburg/Saar von November 2010 bis Oktober 2014. Mein besonderer Dank gilt: Herrn Professor Hans H. Maurer für die Möglichkeit, in seinem Arbeitskreis ein breit gefächertes, vollumfängliches wissenschaftliches Arbeiten zu erlernen. Labor- und Personalverantwortung, analytisches Denken und Durchführen, Diskussion mit ihm, Darstellung der wissenschaftlichen Ergebnisse auf Fachkongressen, all dies prägte und forderte heraus, Herrn Professor Rolf W. Hartmann für die Übernahme des Koreferats, den vor mir gegangenen und länger gebliebenen
    [Show full text]
  • LJMU Research Online
    LJMU Research Online Elliott, SP, Brandt, SD, Wallach, J, Morris, H and Kavanagh, PV First Reported Fatalities Associated with the 'Research Chemical' 2- Methoxydiphenidine http://researchonline.ljmu.ac.uk/id/eprint/3410/ Article Citation (please note it is advisable to refer to the publisher’s version if you intend to cite from this work) Elliott, SP, Brandt, SD, Wallach, J, Morris, H and Kavanagh, PV (2015) First Reported Fatalities Associated with the 'Research Chemical' 2- Methoxydiphenidine. JOURNAL OF ANALYTICAL TOXICOLOGY, 39 (4). pp. 287-293. ISSN 0146-4760 LJMU has developed LJMU Research Online for users to access the research output of the University more effectively. Copyright © and Moral Rights for the papers on this site are retained by the individual authors and/or other copyright owners. Users may download and/or print one copy of any article(s) in LJMU Research Online to facilitate their private study or for non-commercial research. You may not engage in further distribution of the material or use it for any profit-making activities or any commercial gain. The version presented here may differ from the published version or from the version of the record. Please see the repository URL above for details on accessing the published version and note that access may require a subscription. For more information please contact [email protected] http://researchonline.ljmu.ac.uk/ Journal of Analytical Toxicology First reported fatalities associated with the ‘research chemical’ 2’-methoxydiphenidine (MXP) Journal:For Journal Review of Analytical Toxicology Only Manuscript ID: JAT-14-1724.R1 Manuscript Type: Article Date Submitted by the Author: n/a Complete List of Authors: Elliott, Simon; ROAR Forensics, Toxicology Brandt, Simon; Liverpool John Moores University, School of Pharmacy and Biomolecular Sciences Wallach, Jason; Philadelphia College of Pharmacy, Department of Pharmaceutical Sciences Morris, Hamilton; The New School for Social Research, Department of Anthropology Kavanagh, Pierce; Trinity Centre for Health Sciences, St.
    [Show full text]
  • Comprehensive Multi-Analytical Screening Of
    COMPREHENSIVE MULTI-ANALYTICAL SCREENING OF DRUGS OF ABUSE, INCLUDING NEW PSYCHOACTIVE SUBSTANCES, IN URINE WITH BIOCHIP ARRAYS APPLIED TO THE EVIDENCE ANALYSER Darragh J., Keery L., Keenan R., Stevenson C., Norney G., Benchikh M.E., Rodríguez M.L., McConnell R. I., FitzGerald S.P. Randox Toxicology Ltd., Crumlin, United Kingdom e-mail: [email protected] Introduction Biochip array technology allows the simultaneous detection of multiple drugs from a single undivided sample, which This study summarises the analytical performance of three different biochip arrays applied to the screening of increases the screening capacity and the result output per sample. Polydrug consumption can be detected and by acetylfentanyl, AH-7921, amphetamine, barbiturates, benzodiazepines (including etizolam and clonazepam), incorporating new immunoassays on the biochip surface, this technology has the capacity to adapt to the new trends benzoylecgonine/cocaine, benzylpiperazines, buprenorphine, cannabinoids, carfentanil, dextromethorphan, fentanyl, in the drug market. furanylfentanyl, meprobamate, mescaline, methamphetamine, methadone, mitragynine, MT-45, naloxone, ocfentanyl, opioids, opiates, oxycodone, phencyclidine, phenylpiperazines, salvinorin, sufentanil, synthetic cannabinoids (JWH-018, UR-144, AB-PINACA, AB-CHMINACA), synthetic cathinones [mephedrone, methcathinone, alpha- pyrrolidinopentiophenone (alpha-PVP)], tramadol, tricyclic antidepressants, U-47700, W-19, zolpidem. Methodology Three different biochip arrays were used (DOA ULTRA,
    [Show full text]
  • Kormányrendelet
    1. ------IND- 2017 0092 FIN HU- ------ 20170314 --- --- PROJET Kormányrendelet a fogyasztói piacról kitiltott pszichoaktív anyagokról szóló rendelet módosításáról A kormány határozatával összhangban a 899/2016. sz. rendelettel módosított, a fogyasztói piacról kitiltott pszichoaktív anyagokról szóló, 1130/2014 sz. kormányrendelet melléklete a következőképpen módosul: ——— E rendelet 2017. [hónap] [nap]. napján lép hatályba. Helsinki, 2017. [hónap] [nap] Juha Rehula, családügyi és szociális miniszter Elina Kotovirta, miniszteri tanácsos Melléklet 25B-NBF (2-(4-bróm-2,5-dimetoxifenil)-N-[(2-fluorfenil)metil]etán-1-amin) 25B-NBF izomer (2-(4-bróm-2,5-dimetoxifenil)-N-[(3-fluorfenil)metil]etán-1-amin) 25B-NBF izomer (2-(4-bróm-2,5-dimetoxifenil)-N-[(4-fluorfenil)metil]etán-1-amin) 25B-NBOH (2-({[2-(4-bróm-2,5-dimetoxifenil)etil]amino}metil)fenol) 25B-NBOH izomer (3-({[2-(4-bróm-2,5-dimetoxifenil)etil]amino}metil)fenol) 25B-NBOH izomer (4-({[2-(4-bróm-2,5-dimetoxifenil)etil]amino}metil)fenol) 2C-TFM (2-[2,5-dimetoxi-4-(trifluor-metil)fenil]etán-1-amin) 2F-NEB (2-(etilamin)-1-(2-fluorfenil)bután-1-on) 3F-NEB (2-(etilamin)-1-(3-fluorfenil)bután-1-on) 3MeO-PCMo (4-[1-(3-metoxifenil)ciklohexil]morfolin) 4F-NEB (2-(etilamin)-1-(4-fluorfenil)bután-1-on) 4MeO-PCMo (4-[1-(4-metoxifenil)ciklohexil]morfolin) 5F-ADB-PINACA (N-(1-amino-3,3-dimetil-1-oxobután-2-il)-1-(5-fluorpentil)-1H-indazol-3- karboxamid) 5F-EDMB-PINACA (etil N-[1-(5-fluorpentil)-1H-indazol-3-karbonil]-3-metilvalinát) 5F-MDMB-PICA (N-[1-(5-fluorpentil)-1H-indol-3-karbonil]-3-metilvalinát)
    [Show full text]
  • Model Scheduling New/Novel Psychoactive Substances Act (Third Edition)
    Model Scheduling New/Novel Psychoactive Substances Act (Third Edition) July 1, 2019. This project was supported by Grant No. G1799ONDCP03A, awarded by the Office of National Drug Control Policy. Points of view or opinions in this document are those of the author and do not necessarily represent the official position or policies of the Office of National Drug Control Policy or the United States Government. © 2019 NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS. This document may be reproduced for non-commercial purposes with full attribution to the National Alliance for Model State Drug Laws. Please contact NAMSDL at [email protected] or (703) 229-4954 with any questions about the Model Language. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: NATIONAL ALLIANCE FOR MODEL STATE DRUG 1 LAWS, 1335 North Front Street, First Floor, Harrisburg, PA, 17102-2629. Model Scheduling New/Novel Psychoactive Substances Act (Third Edition)1 Table of Contents 3 Policy Statement and Background 5 Highlights 6 Section I – Short Title 6 Section II – Purpose 6 Section III – Synthetic Cannabinoids 13 Section IV – Substituted Cathinones 19 Section V – Substituted Phenethylamines 23 Section VI – N-benzyl Phenethylamine Compounds 25 Section VII – Substituted Tryptamines 28 Section VIII – Substituted Phenylcyclohexylamines 30 Section IX – Fentanyl Derivatives 39 Section X – Unclassified NPS 43 Appendix 1 Second edition published in September 2018; first edition published in 2014. Content in red bold first added in third edition. © 2019 NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS. This document may be reproduced for non-commercial purposes with full attribution to the National Alliance for Model State Drug Laws.
    [Show full text]
  • TESTIMONY of CASEY OWEN DURST Director of Field Operations
    TESTIMONY OF CASEY OWEN DURST Director of Field Operations Baltimore Field Office Office of Field Operations U.S. Customs and Border Protection Department of Homeland Security For a Hearing BEFORE U.S. House of Representatives Committee on Homeland Security Subcommittee on Oversight and Management Efficiency ON “Combating Opioid Smuggling” June 19, 2018 Harrisburg, Pennsylvania Introduction Chairman Perry, Ranking Member Correa, and distinguished Members of the Subcommittee, thank you for the opportunity to appear today to discuss the role of U.S. Customs and Border Protection (CBP) in combating the flow of opioids, including synthetic opioids such as fentanyl, into the United States. The opioid crisis is one of the most important, complex, and difficult challenges our Nation faces today, and was declared a National Emergency by President Donald Trump in October of last year.1 As America’s unified border agency, CBP plays a critical role in preventing illicit narcotics, including opioids, from reaching the American public. CBP leverages targeting and intelligence- driven strategies, and works in close coordination with our partners as part of our multi-layered, risk-based approach to enhance the security of our borders and our country. This layered approach reduces our reliance on any single point or program, and extends our zone of security outward, ensuring our physical border is not the first or last line of defense, but one of many. Opioid Trends, Interdictions, and Challenges In Fiscal Year (FY) 2018 to-date, the efforts of Office of Field Operations (OFO) and U.S. Border Patrol (USBP) personnel resulted in the seizure of more than 545,000 lbs.
    [Show full text]
  • Appendix-2Final.Pdf 663.7 KB
    North West ‘Through the Gate Substance Misuse Services’ Drug Testing Project Appendix 2 – Analytical methodologies Overview Urine samples were analysed using three methodologies. The first methodology (General Screen) was designed to cover a wide range of analytes (drugs) and was used for all analytes other than the synthetic cannabinoid receptor agonists (SCRAs). The analyte coverage included a broad range of commonly prescribed drugs including over the counter medications, commonly misused drugs and metabolites of many of the compounds too. This approach provided a very powerful drug screening tool to investigate drug use/misuse before and whilst in prison. The second methodology (SCRA Screen) was specifically designed for SCRAs and targets only those compounds. This was a very sensitive methodology with a method capability of sub 100pg/ml for over 600 SCRAs and their metabolites. Both methodologies utilised full scan high resolution accurate mass LCMS technologies that allowed a non-targeted approach to data acquisition and the ability to retrospectively review data. The non-targeted approach to data acquisition effectively means that the analyte coverage of the data acquisition was unlimited. The only limiting factors were related to the chemical nature of the analyte being looked for. The analyte must extract in the sample preparation process; it must chromatograph and it must ionise under the conditions used by the mass spectrometer interface. The final limiting factor was presence in the data processing database. The subsequent study of negative MDT samples across the North West and London and the South East used a GCMS methodology for anabolic steroids in addition to the General and SCRA screens.
    [Show full text]